Use of Genetic Mouse Models in the Study of Diabetic Nephropathy

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2004 Apr 8

PMID 15068744

Citations 15

Authors

Terri J Allen

Mark E Cooper

Hui Y Lan

Affiliations

Soon will be listed here.

Abstract

The study of experimental diabetic nephropathy in rodent models has led to many changes in the clinical management of human diabetic nephropathy. With the development of technology to generate knockout and transgenic animals, the mouse has become a favored species in medical research. There are several genetic mouse models of diabetes, with the majority being models of type 2 diabetes mellitus. These include the hypoinsulinemic non-obese diabetic mouse, the Kkay mouse, the New Zealand obese mouse, the hyperinsulinemic ob/ob mouse, and the different strains of obese hyperinsulinemic db/db mouse. Each of these models displays some renal changes, but by far the best model of renal disease and the one that is the most studied is the db/db mouse. The db/db mouse displays substantial glomerular pathology, including mesangial matrix expansion and modest albuminuria. It has been reported that the db/db mouse has a decline in creatinine clearance after 5 months of age, but more specific approaches are warranted to confirm these findings. A number of intervention studies show renoprotection in this model. Although mice have many advantages, such as being able to be cross-bred with genetically manipulated animals, in many ways they are not very similar to humans, and in some respects the rat may be a better choice, particularly in relation to some features of end-organ injury.

Citing Articles

Renal Lipid Alterations From Diabetes to Early-Stage Diabetic Kidney Disease and Mitophagy: Focus on Cardiolipin.

Li Z, Wang H, Liu N, Lan X, Xie A, Yuan G J Cell Mol Med. 2025; 29(3):e70419.

PMID: 39936909 PMC: 11816159. DOI: 10.1111/jcmm.70419.

High CD133 expression in proximal tubular cells in diabetic kidney disease: good or bad?.

Zhang Y, Xu L, Guo C, Li X, Tian Y, Liao L J Transl Med. 2024; 22(1):159.

PMID: 38365731 PMC: 10870558. DOI: 10.1186/s12967-024-04950-0.

Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates.

Habas Sr E, Al Adab A, Arryes M, Alfitori G, Farfar K, Habas A Cureus. 2023; 15(10):e46737.

PMID: 38022248 PMC: 10631488. DOI: 10.7759/cureus.46737.

Protective Effects of Ethanolic Extract from Rhizome of against Renal Fibrosis and Inflammation in a Diabetic Nephropathy Model.

Yoon J, Park J, Lee Y, Kim H, Han B, Jin H Int J Mol Sci. 2021; 22(13).

PMID: 34281284 PMC: 8267752. DOI: 10.3390/ijms22137230.

Systematic review and meta-analysis of mouse models of diabetes-associated ulcers.

Huynh P, Phie J, Krishna S, Golledge J BMJ Open Diabetes Res Care. 2020; 8(1).

PMID: 32467222 PMC: 7259859. DOI: 10.1136/bmjdrc-2019-000982.

References

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

Hummel K, Coleman D, Lane P . The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains. Biochem Genet. 1972; 7(1):1-13. DOI: 10.1007/BF00487005. View

Wilson K, Eckenrode S, Li Q, Ruan Q, Yang P, Shi J . Microarray analysis of gene expression in the kidneys of new- and post-onset diabetic NOD mice. Diabetes. 2003; 52(8):2151-9. DOI: 10.2337/diabetes.52.8.2151. View

A Wahab N, Yevdokimova N, Weston B, Roberts T, Li X, Brinkman H . Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J. 2001; 359(Pt 1):77-87. PMC: 1222123. DOI: 10.1042/0264-6021:3590077. View

Gartner K . Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (c57bl/6j db/db and c57bl/ksj db/db). Diabetologia. 1978; 15(1):59-63. DOI: 10.1007/BF01219330. View

Zatz R, Dunn B, Meyer T, Anderson S, Rennke H, Brenner B . Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986; 77(6):1925-30. PMC: 370553. DOI: 10.1172/JCI112521. View

Lee S, Graham A . Early immunopathologic events in experimental diabetic nephropathy: a study in db/db mice. Exp Mol Pathol. 1980; 33(3):323-32. DOI: 10.1016/0014-4800(80)90030-1. View

Flyvbjerg A, Denner L, Schrijvers B, Tilton R, Mogensen T, Paludan S . Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 2003; 53(1):166-72. DOI: 10.2337/diabetes.53.1.166. View

Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S . Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000; 14(3):439-47. DOI: 10.1096/fasebj.14.3.439. View

10.

Ziyadeh F, Hoffman B, Han D, Iglesias-de la Cruz M, Hong S, Isono M . Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000; 97(14):8015-20. PMC: 16662. DOI: 10.1073/pnas.120055097. View

11.

Meyer M, Meyer Jr R, Gray R, Irwin R . Picric acid methods greatly overestimate serum creatinine in mice: more accurate results with high-performance liquid chromatography. Anal Biochem. 1985; 144(1):285-90. DOI: 10.1016/0003-2697(85)90118-6. View

12.

Maeda M, Yabuki A, Suzuki S, Matsumoto M, Taniguchi K, Nishinakagawa H . Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse: acute phase of diabetes. Vet Pathol. 2003; 40(2):187-95. DOI: 10.1354/vp.40-2-187. View

13.

Forbes J, Thallas V, Thomas M, Founds H, Burns W, Jerums G . The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003; 17(12):1762-4. DOI: 10.1096/fj.02-1102fje. View

14.

Cohen M, Clements R, Hud E, Cohen J, Ziyadeh F . Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol. 1996; 4(3):166-71. View

15.

Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H . Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002; 18(3):224-37. DOI: 10.1002/dmrr.283. View

16.

Yang C, Hattori M, Vlassara H, He C, Carome M, Yamato E . Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol. 1995; 5(8):1610-7. DOI: 10.1681/ASN.V581610. View

17.

ANDERS H, Schlondorff D . Murine models of renal disease: possibilities and problems in studies using mutant mice. Exp Nephrol. 2000; 8(4-5):181-93. DOI: 10.1159/000020667. View

18.

Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M . Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000; 58(4):1492-9. DOI: 10.1046/j.1523-1755.2000.00311.x. View

19.

Sharma K, Ziyadeh F . Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes. 1995; 44(10):1139-46. DOI: 10.2337/diab.44.10.1139. View

20.

Chow F, Ozols E, Nikolic-Paterson D, Atkins R, Tesch G . Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2003; 65(1):116-28. DOI: 10.1111/j.1523-1755.2004.00367.x. View